Allogene Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Allogene Therapeutics, Inc. filed a Form 8-K dated March 10, 2023, under Item 7.01, Regulation FD Disclosure. The filing addresses the company’s banking exposure to Silicon Valley Bank; it is not a periodic financial results filing.
Financial Metrics and Liquidity
The company stated that it did not hold cash deposits or securities at Silicon Valley Bank. The filing does not provide revenue, profit, cash flow, margin, debt, total liquidity, or other financial metrics.
Material Changes Versus Prior Period
No period-over-period financial comparison or other material operating change is disclosed.
Outlook, Risks, and Unusual Items
The disclosure appears intended to clarify that Allogene had no cash deposits or securities at Silicon Valley Bank. No guidance, outlook, contingency, or broader banking-risk assessment is provided.
The Item 7.01 information is furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act. It will not be incorporated by reference into registration statements or other documents under the Securities Act.
Key Facts to Verify
- Confirm the company’s statement that it held no cash deposits or securities at Silicon Valley Bank as of the disclosure date.
- Review subsequent filings for any changes in banking relationships, liquidity, or financial exposure.
- Consult the company’s periodic reports for cash, debt, operating results, and liquidity information not included in this 8-K.